Adverse events of special interest (AESI) such as Bell’s palsy and narcolepsy often present to primary care settings rather than hospitals and COVID-19 vaccine pharmacovigilance using hospital data only will miss these cases.
The GVDN® is a technical partner with the African COVID-19 Vaccine Safety Surveillance (ACVaSS) project.* Hospital-based sentinel surveillance designed to detect safety signals of rare adverse events of special interest (AESIs) or to evaluate safety signals arising from other sources,
The BRAVE project* will develop infrastructure for post-authorisation vaccine safety surveillance in low- and middle-income countries (LMICs) and identify the rates of potential adverse events of special interest (AESI) before the introduction of new vaccines.
Epidemiological assessment of adverse events following measles, mumps, and rubella (MMR) vaccination
This is a self-controlled case series (SCCS) study of a cohort of children aged 0–5 years who were born in 2008–2019 and are resident in New Zealand to investigate the association between MMR vaccination and a list of specified conditions.
The Genomics of COVID-19 Vaccine-Related Adverse Events project is one of the Global COVID Vaccine Safety (GCoVS) project* activities.
The simultaneous development of so many vaccines for COVID-19 and their anticipated deployment in both high- and low-middle- income countries to meet the global need is unprecedented.
The New Zealand Gold Study includes a suite of observational studies to assess the risk of adverse events of special interest following COVID-19 and mpox vaccines in Aotearoa New Zealand using a gold standard approach. The work also includes contribution to a genomics study.
